IMR Press / EJGO / Volume 25 / Issue 6 / pii/2004266

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations

Show Less
1 Section of Endocrinology and Menopause, University Women's Hospital, Tuebingen (Germany)
Eur. J. Gynaecol. Oncol. 2004, 25(6), 699–701;
Published: 10 December 2004

Purpose of investigation: The endogenous estradiol metabolite, 2-methoxyestradiol (2ME), has been shown to be a potent inhibitor of cell growth and a strong anti-angiogenic substance. We investigated for the first time whether in vitro combinations of 2ME with various chemotherapeutic compounds may result in an additive inhibitory effect on the proliferation of human ovary cancer cells. Method: As a model two different human ovary cancer cell lines were used. All cell lines were incubated with equimolar con­centrations of 2ME (0.8-25 µM) and the chemotherapeutics epirubicine, doxorubicine, paclitaxel, docetaxel, carboplatin, vinorel­bine, 5-fluorouracil and mafosfamide. Proliferation was measured after four days using the ATP-chemosensitivity test. Results: For both ovary cancer cell lines a significant additive effect of 2ME with epirubicine and carboplatin was observed at the lower concentration range of these chemotherapeutic substances. Conclusion: 2ME is able to enhance the antiproliferative activity of certain chemotherapeutics at pharmacological relevant con­centrations. This estradiol metabolite is currently in a phase II trial in patients with refractary metastatic breast cancer and the tol­erability has been shown to be very good. The combination of 2ME with chemotherapeutics may therefore offer a new clinically relevant treatment regimen for hormone-dependent cancer.

Ovary cancer cells
Back to top